bullish
Paradigm Biopharmaceuticals (PAR AU): Comfortable Funding Position Through 2024
Tina has highlighted this Insight as a Top Pick
300 Views17 Aug 2022 21:58
SUMMARY
- Paradigm Biopharmaceuticals (PAR AU) announced A$66 million capital raising, comprising A$45.7 million institutional placement and rights issue offer of A$20.3 million at A$1.30 per share.
- At the completion of the transaction, Paradigm will have a proforma cash position of $108.5 million, which funds the company into 2024.
- Paradigm is expected to announce data from one of its key trials related to knee OA pain in September, which will be a near-term catalyst for the company.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Paradigm Biopharmaceuticals (PAR AU): Positive Result from Phase 2 Trial; Satisfactory Cash Position18 Oct 2023
- Paradigm Biopharmaceuticals (PAR AU): Comfortable Funding Position Through 202417 Aug 2022
- Paradigm Biopharmaceuticals (PAR AU): Concerns Persist Amid Deteriorating Financials14 Mar 2022
- Paradigm Biopharmaceuticals (PAR AU): Concerns on First Potentially Commercialized Product11 Jan 2022
x